Research and Development

Wesana Health Outlines Accelerated Drug Development Pathway

Wesana Health Outlines Accelerated Drug Development Pathway May 10, 2022 07:30 ET  CHICAGO and TORONTO, May 10, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB:…

read more
150 150 Wesana Health

Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013

Pre-IND Meeting is a Significant Milestone in the Clinical Development of SANA-013, Defining the Pathway to Initiate in-Human Clinical Trials in Q4 2022 CHICAGO and TORONTO, March 14, 2022 (GLOBE…

read more
150 150 Wesana Health

Wesana Health Announces Positive Findings From Animal Study on Novel Depression Treatment Protocol Combining Psilocybin and Cannabidiol

Wesana’s novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a microdose of psilocybin combined with cannabidiol, significantly reduced…

read more
150 150 Wesana Health

Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

The meeting is scheduled for March 11, 2022 CHICAGO and TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc.  (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data driven…

read more
150 150 Wesana Health
Start Typing